Ashford Capital Management Inc. Has $18.56 Million Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Ashford Capital Management Inc. increased its stake in Supernus Pharmaceuticals by 3.8%, acquiring an additional 20,781 shares, bringing its total ownership to 566,556 shares, which represents 2.4% of its portfolio.
• Brokerages have recently upgraded Supernus Pharmaceuticals' stock rating, with Zacks Research raising it from "strong sell" to "hold," while Piper Sandler and Cantor Fitzgerald increased price targets for the stock.
• Supernus Pharmaceuticals' stock has a 52-week range between $29.16 and $45.60, closing at $45.12, and a market capitalization of $2.53 billion.

Ashford Capital Management Inc. raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.8% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 566,556 shares of the specialty pharmaceutical company's stock after buying an additional 20,781 shares during the quarter. Supernus Pharmaceuticals makes up about 2.4% of Ashford Capital Management Inc.'s investment portfolio, making the stock its 20th largest holding. Ashford Capital Management Inc. owned about 1.01% of Supernus Pharmaceuticals worth $18,555,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Supernus Pharmaceuticals by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock worth $1,033,000 after acquiring an additional 1,083 shares in the last quarter. Two Sigma Advisers LP grew its stake in Supernus Pharmaceuticals by 14.7% during the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after acquiring an additional 1,000 shares in the last quarter. Principal Financial Group Inc. grew its stake in Supernus Pharmaceuticals by 3.2% during the 1st quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after acquiring an additional 9,590 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Supernus Pharmaceuticals by 63.6% in the 1st quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after buying an additional 6,867 shares in the last quarter. Finally, Quantinno Capital Management LP grew its stake in shares of Supernus Pharmaceuticals by 11.5% in the 4th quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock valued at $304,000 after buying an additional 864 shares in the last quarter.

Supernus Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ:SUPN traded up $0.39 during trading on Wednesday, hitting $44.93. 553,192 shares of the company were exchanged, compared to its average volume of 640,130. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of 39.07 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $45.94. The firm has a fifty day moving average price of $37.15 and a two-hundred day moving average price of $33.98.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $44.51, for a total value of $623,140.00. Following the transaction, the senior vice president directly owned 15,496 shares of the company's stock, valued at $689,726.96. This represents a 47.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Frederick M. Hudson sold 7,457 shares of the company's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total value of $315,132.82. Following the completion of the transaction, the director directly owned 46,307 shares in the company, valued at approximately $1,956,933.82. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 179,606 shares of company stock worth $7,617,005 in the last three months. 8.80% of the stock is owned by insiders.

Analysts Set New Price Targets

SUPN has been the subject of several recent research reports. Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Cantor Fitzgerald raised their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Piper Sandler raised their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Friday, August 29th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.